Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3432-3441

  Lestner, Jodi M ^a   Howard, Susan J ^a   Goodwin, Joanne ^a   Gregson, Lea ^a   Majithiya, Jayesh ^a   Walsh, Thomas J ^b   Jensen, Gerard M ^c   Hope, William W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Gilead Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; GALACTOMANNAN; SULFORHODAMINE B;

AREA UNDER THE CURVE; ARTICLE; DRUG PENETRATION; ENDOTHELIUM CELL; FUNGUS HYPHAE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG ASPERGILLOSIS; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CELL LINE; DEOXYCHOLIC ACID; DRUG COMBINATIONS; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; LUNG DISEASES, FUNGAL; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PULMONARY ALVEOLI;

EID: 77955358447     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01586-09     Document Type: Article

References (27)

1. Adler-Moore, J. P., and R. T. Proffitt. 2008. Amphotericin B lipid preparations: what are the differences? Clin. Microbiol. Infect. 14(Suppl. 4):25-36.
2. Andes, D., N. Safdar, K. Marchillo, and R. Conklin. 2006. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipidassociated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50:674-684.
3. Bates, D. W., L. Su, D. T. Yu, G. M. Chertow, D. L. Seger, D. R. Gomes, E. J. Dasbach, and R. Platt. 2001. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32:686-693.
4. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:834-840.
5. Berenguer, J., M. C. Allende, J. W. Lee, K. Garrett, C. Lyman, N. M. Ali, J. Bacher, P. A. Pizzo, and T. J. Walsh. 1995. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone- induced immunosuppression. Am. J. Respir. Crit. Care Med. 152:1079-1086.
6. Bermudez, L. E., F. J. Sangari, P. Kolonoski, M. Petrofsky, and J. Goodman. 2002. The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells. Infect. Immun. 70:140-146.
7. CLSI/NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Cornely, O. A., J. Maertens, M. Bresnik, R. Ebrahimi, A. J. Ullmann, E. Bouza, C. P. Heussel, O. Lortholary, C. Rieger, A. Boehme, M. Aoun, H. A. Horst, A. Thiebaut, M. Ruhnke, D. Reichert, N. Vianelli, S. W. Krause, E. Olavarria, and R. Herbrecht. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a highloading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289-1297.
9. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.esc.edu/.
10. Drusano, G. L. 2005. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 25:150S-158S.
11. Groll, A. H., C. A. Lyman, V. Petraitis, R. Petraitiene, D. Armstrong, D. Mickiene, R. M. Alfaro, R. L. Schaufele, T. Sein, J. Bacher, and T. J. Walsh. 2006. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 50:3418-3423.
12. Hope, W. W. 2009. Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. Med. Mycol. 47(Suppl. 1):S291-S298.
13. Hope, W. W., and G. L. Drusano. 2009. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin. Microbiol. Infect. 15:602-612.
14. Hope, W. W., G. L. Drusano, C. B. Moore, A. Sharp, A. Louie, T. J. Walsh, D. W. Denning, and P. A. Warn. 2007. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob. Agents Chemother. 51:285-295.
15. Hope, W. W., M. J. Kruhlak, C. A. Lyman, R. Petraitiene, V. Petraitis, A. Francesconi, M. Kasai, D. Mickiene, T. Sein, J. Peter, A. M. Kelaher, J. E. Hughes, M. P. Cotton, C. J. Cotten, J. Bacher, S. Tripathi, L. Bermudez, T. K. Maugel, P. M. Zerfas, J. R. Wingard, G. L. Drusano, and T. J. Walsh. 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J. Infect. Dis. 195:455-466.
16. Jensen, J. M., C. R. Skenes, T. H. Bunch, N. Weissman, N. Amirghahari, A. Satorius, K. L. Moynihan, and C. G. S. Eley. 1999. Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay. Drug Delivery 6:81-88.
17. Lass-Flörl, C., A. Mayr, S. Perkhofer, G. Hinterberger, J. Hausdorfer, C. Speth, and M. Fille. 2008. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52:3637-3641.
18. Latgé, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310-350.
19. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
20. Lewis, R. E., G. Chamilos, R. A. Prince, and D. P. Kontoyiannis. 2007. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob. Agents Chemother. 51:1078-1081.
21. Mehta, R. T., T. J. McQueen, A. Keyhani, and G. Lopez-Berestein. 1994. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 40:256-264.
22. Nivoix, Y., M. Velten, V. Letscher-Bru, A. Moghaddam, S. Natarajan-Ame, C. Fohrer, B. Lioure, K. Bilger, P. Lutun, L. Marcellin, A. Launoy, G. Freys, J. P. Bergerat, and R. Herbrecht. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47:1176-1184.
23. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
24. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
25. Walsh, T. J., R. W. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, D. Bodensteiner, P. Pappas, N. Seibel, R. N. Greenberg, S. Dummer, M. Schuster, and J. S. Holcenberg. 1999. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340:764-771.
26. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
27. Wingard, J. R., P. Kubilis, L. Lee, G. Yee, M. White, L. Walshe, R. Bowden, E. Anaissie, J. Hiemenz, and J. Lister. 1999. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29:1402-1407.